FDA Considers Easing Restrictions on Peptide Injections Amid Safety Concerns
The Food and Drug Administration (FDA) is evaluating the possibility of allowing compounding pharmacies to produce seven peptides that are currently restricted due to safety concerns. This move comes as peptides gain popularity for their purported wellness and anti-aging benefits, despite many claims remaining untested. Health Secretary Robert F. Kennedy Jr. has expressed support for making peptides more accessible, citing the need to curb the illicit market that has emerged due to current restrictions. The FDA's advisory panel on pharmacy compounding is set to discuss the potential use of these peptides for various conditions, including ulcerative colitis and obesity, in a meeting scheduled for late July. The agency has previously categorized certain peptides as too risky for compounding, but the growing demand and unauthorized sales have prompted a reevaluation. 
